Risk factors for developing triple-negative breast cancer

Breast cancer is the most common cancer in women. Among the 1.67 million women diagnosed each year, 15% are diagnosed with triple-negative breast cancer (TNBC). More common in women under the age of 50, TNBC has limited treatment options and is associated with particularly poor survival rates. Knowing the signs and symptoms of breast cancer is essential for early diagnosis and treatment.

For more information on TNBC, visit https://www.roche.com/dam/jcr:83655b8...


Subscribe to our YouTube channel now: https://www.youtube.com/user/r....oche?sub_confirmatio

Get in touch with us:

https://www.roche.com/
https://www.facebook.com/RocheCareers
https://www.linkedin.com/company/roche
https://twitter.com/roche

Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

For more information and insights visit: https://www.roche.com/